Europe Autoinjectors Market Size & Forecast 2020-2026

Europe Autoinjectors Market By Type (Disposable autoinjectors and Reusable autoinjectors), By Application (Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications), By End Use (Hospitals & Clinics and Home care settings), By Country, Industry Analysis and Forecast, 2020 - 2026

Published Date: January-2021 | Number of Pages: 97 | Format: PDF | Report ID: KBV-14110

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Autoinjectors Market, by Type
1.4.2 Europe Autoinjectors Market, by Application
1.4.3 Europe Autoinjectors Market, by End Use
1.4.4 Europe Autoinjectors Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Geographical Expansions
3.2.4 Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, May – 2020, Nov) Leading Players

Chapter 4. Europe Autoinjectors Market by Type
4.1 Europe Disposable autoinjectors Market by Country
4.2 Europe Reusable autoinjectors Market by Country

Chapter 5. Europe Autoinjectors Market by Application
5.1 Europe Anaphylaxis Market by Country
5.2 Europe Rheumatoid Arthritis Market by Country
5.3 Europe Multiple Sclerosis Market by Country
5.4 Europe Other Application Market by Country

Chapter 6. Europe Autoinjectors Market by End Use
6.1 Europe Hospitals & Clinics Autoinjectors Market by Country
6.2 Europe Home care settings Autoinjectors Market by Country

Chapter 7. Europe Autoinjectors Market by Country
7.1 Germany Autoinjectors Market
7.1.1 Germany Autoinjectors Market by Type
7.1.2 Germany Autoinjectors Market by Application
7.1.3 Germany Autoinjectors Market by End Use
7.2 UK Autoinjectors Market
7.2.1 UK Autoinjectors Market by Type
7.2.2 UK Autoinjectors Market by Application
7.2.3 UK Autoinjectors Market by End Use
7.3 France Autoinjectors Market
7.3.1 France Autoinjectors Market by Type
7.3.2 France Autoinjectors Market by Application
7.3.3 France Autoinjectors Market by End Use
7.4 Russia Autoinjectors Market
7.4.1 Russia Autoinjectors Market by Type
7.4.2 Russia Autoinjectors Market by Application
7.4.3 Russia Autoinjectors Market by End Use
7.5 Spain Autoinjectors Market
7.5.1 Spain Autoinjectors Market by Type
7.5.2 Spain Autoinjectors Market by Application
7.5.3 Spain Autoinjectors Market by End Use
7.6 Italy Autoinjectors Market
7.6.1 Italy Autoinjectors Market by Type
7.6.2 Italy Autoinjectors Market by Application
7.6.3 Italy Autoinjectors Market by End Use
7.7 Rest of Europe Autoinjectors Market
7.7.1 Rest of Europe Autoinjectors Market by Type
7.7.2 Rest of Europe Autoinjectors Market by Application
7.7.3 Rest of Europe Autoinjectors Market by End Use

Chapter 8. Company Profiles
8.1 Eli Lilly and Company
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Geographical Expansions:
8.2 GlaxoSmithKline PLC (GSK)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.1 Recent strategies and developments:
8.2.1.1 Approvals:
8.3 Merck Group
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.4 Sanofi S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Approvals:
8.4.5.3 Product Launches and Product Expansions:
8.5 Becton, Dickinson and Company
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Product Launches and Product Expansions:
8.6 Teva Pharmaceutical Industries Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.6.5.3 Approvals:
8.7 Amgen, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expense
8.7.4 Recent strategies and developments:
8.7.4.1 Product Launches and Product Expansions:
8.8 Ypsomed AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 AbbVie, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.10. Biogen, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities